Navigation Links
Genmab Reaches Fifth Milestone in Ofatumumab Collaboration
Date:8/21/2008

Summary: Genmab Will Receive a Milestone Payment of Approximately DKK 232.7 Million From GSK for Achievement of Positive Results in the Phase III CLL

Study

COPENHAGEN, August 21 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the fifth milestone for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately DKK 232.7 million (approximately USD 48.5 million) was triggered by the achievement of positive results in the Phase III study of ofatumumab in refractory chronic lymphocytic leukemia (CLL). Genmab has received an approximate total of DKK 552 million (approximately USD 110 million) in milestone payments under the collaboration so far.

"While achievement of this milestone represents an important potential turning point for Genmab," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab, "it is even more important for CLL patients who are waiting for new treatments to combat their difficult to treat disease."

Ofatumumab is an investigational new generation fully human monoclonal antibody that targets a distinct, membrane proximal, small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat CLL, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting Multiple Sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases inclu
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- , Not for release, publication or distribution ... jurisdiction where to do so would constitute a violation of ... ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG ... has held a meeting with representatives of AbbVie. ... agreement or approval of AbbVie. A further update ...
(Date:7/11/2014)... 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) ... (eslicarbazepine acetate) for use as a once-daily adjunctive therapy ... epilepsy who are not satisfactorily controlled with conventional therapy. ... patients under 18 years of age. ... and according to Epilepsy Canada, it affects 0.6% of ...
(Date:7/10/2014)... Product and process impurities in ... and are often “lost in the noise,” making ... presenters Dr. Rowel Tobias, Senior Scientist, Protein Chemistry ... of Quality at Nanotherapeutics, Inc., to lear about ... detection and quantitation while achieving the required specificity ...
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, and ... purchased a DNA test to unravel the ... a lifetime of memories, sharing, and closeness. In fact, ... genuinely brought the family closer together. , Recently, ... history and prior to taking the genetic ancestry ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Inc. (Nasdaq: EVVV ),a global endovascular device ... its Board of Directors effective immediately. , ... president and chief executive officer of CCS,Medical, a privately ... diseases such as diabetes, wound care, urology and respiratory,disorders. ...
... and PHILADELPHIA, Dec. 3 GlaxoSmithKline,(LSE/NYSE: GSK ) ... a,pending lawsuit in the previously announced tender offer to purchase ... Inc.,(Nasdaq: GNLB ), for $1.30 per share in ... It is a condition to ...
... Dec. 3 CeloNova BioSciences, Inc., announced,today that ... is commercializing the,CATANIA(TM) Coronary Stent System with NanoThin ... any stent thrombosis in clinical studies. It is ... now some Middle,Eastern countries with aggressive world-wide expansion ...
Cached Biology Technology:ev3 Inc. Appoints John L. Miclot to Board of Directors 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 2CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 3
(Date:7/11/2014)... July 3, 2014, Shenzhen, China Researchers from Salk ... for the first time evaluated the safety and ... and successfully developed a new method, TALEN-HDAdV, which ... pluripotent stem cell (hiPSC). This study published online ... important theoretical foundation for stem cell-based gene therapy. ...
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
(Date:7/11/2014)... that under the normal circumstances, astrocytes participate ... neuronal environment, and exhibit therapeutic and repairing ... Previous studies have found that nerve cells ... induction have reduced viability, which produces influences ... Yuan, Kailuan General Hospital, Hebei United University, ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... learning to swim? Thrashing around, floundering, until suddenly it ... of doggy-paddle propel you away from your parent's arms. ... swimmers. Actually, fish larvae are pretty feeble when it ... Dr Ulrike Müller from Wageningen University studies how fish ...
... breast cancer is the lack of inexpensive, early detection ... Michigan hope to change that by developing a device ... with breast cancer. The team won a Breast Cancer ... reward research proposals that could lead to critical advancements ...
... show that regular use of popular prescription pain relievers may ... percent and may offer similar benefit in the prevention of ... were released today at the annual meeting of the American ... believe this is the first study to show that selective ...
Cached Biology News:Even fish don't swim well when they're young! 2Researchers win money to develop breath test to detect breast cancer 2COX-2 inhibitors significantly reduce risk of cancer 2
prototype Nco I...
... is aseptically collected via cardiac puncture from 3 ... mixed sex). It is then centrifuged and frozen ... filtered and bottled at 4C then stored at ... HAVE ALWAYS USED PEL-FREEZ COMPLEMENT, YOU CAN NOW ...
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Performance, mycoplasma, virus, and endotoxin tested...
Biology Products: